Supplementary Figure 3 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

crossref(2023)

引用 0|浏览13
暂无评分
摘要

Supplementary Figure 3

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要